OBJECTIVE: A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy. METHODS: Eligible patients were to have measurable disease and one prior chemotherapy regimen which could include cisplatin or carboplatin. Oxaliplatin 130 mg/m2 was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy. RESULTS: Fifty-four patients were entered on study, of which 52 were eligible and 50 had had prior platinum therapy. The overall response rate was 13.5%, with three patients (5.8%) achieving a complete response and four patients (7.7%) achieving a partial response. Median duration of response was 10.9+ (range: 4.1-50.3+) months. Stable disease was reported in 15 (28.8%) patients, with an associated median duration of 5.4 (range: 2.2-19.6) months. Drug-related toxicities consisted of anemia, nausea and vomiting, and neurotoxicity. CONCLUSIONS: Oxaliplatin at the dose and schedule employed has limited activity in patients with advanced or recurrent endometrial carcinoma who have had previous platinum therapy.
OBJECTIVE: A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with advanced or recurrent endometrial cancer who had received one prior platinum therapy. METHODS: Eligible patients were to have measurable disease and one prior chemotherapy regimen which could include cisplatin or carboplatin. Oxaliplatin 130 mg/m2 was administered intravenously over 2 h. This treatment was repeated every 21 days until progression of disease or adverse effects prohibited further therapy. RESULTS: Fifty-four patients were entered on study, of which 52 were eligible and 50 had had prior platinum therapy. The overall response rate was 13.5%, with three patients (5.8%) achieving a complete response and four patients (7.7%) achieving a partial response. Median duration of response was 10.9+ (range: 4.1-50.3+) months. Stable disease was reported in 15 (28.8%) patients, with an associated median duration of 5.4 (range: 2.2-19.6) months. Drug-related toxicities consisted of anemia, nausea and vomiting, and neurotoxicity. CONCLUSIONS:Oxaliplatin at the dose and schedule employed has limited activity in patients with advanced or recurrent endometrial carcinoma who have had previous platinum therapy.
Authors: Kathleen N Moore; Michael W Sill; Meaghan E Tenney; Christopher J Darus; David Griffin; Theresa L Werner; Peter G Rose; Robert Behrens Journal: Gynecol Oncol Date: 2015-07-11 Impact factor: 5.482
Authors: Brian M Slomovitz; Yunyun Jiang; Melinda S Yates; Pamela T Soliman; Taren Johnston; Maureen Nowakowski; Charles Levenback; Qian Zhang; Kari Ring; Mark F Munsell; David M Gershenson; Karen H Lu; Robert L Coleman Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Rachel Nicole Grisham; Christina Adaniel; David M Hyman; Weining Ma; Alexia Iasonos; Carol Aghajanian; Jason Konner Journal: Int J Gynecol Cancer Date: 2012-06 Impact factor: 3.437
Authors: Don S Dizon; John A Blessing; D Scott McMeekin; Sudarshan K Sharma; Paul Disilvestro; Ronald D Alvarez Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Hadley Sharp; John C Morris; Carter Van Waes; David Gius; Theresa Cooley-Zgela; Anurag K Singh Journal: Am J Clin Oncol Date: 2008-12 Impact factor: 2.339
Authors: Maria M Rubinstein; David M Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Martee L Hensley; Tiffany Troso-Sandoval; Paul Sabbatini; Joyce Guillen; S Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker Journal: Cancer Date: 2019-12-27 Impact factor: 6.860